These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38858192)

  • 1. [Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)].
    Chinese Society of Hepatology, Chinese Medical Association
    Zhonghua Gan Zang Bing Za Zhi; 2024 May; 32(5):418-434. PubMed ID: 38858192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso).
    Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C
    Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
    Fan JG; Wei L; Zhuang H;
    J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
    [No Abstract]   [Full Text] [Related]  

  • 4. NONALCOHOLIC FATTY LIVER DISEASE BRAZILIAN SOCIETY OF HEPATOLOGY CONSENSUS.
    Cotrim HP; Parise ER; Figueiredo-Mendes C; Galizzi-Filho J; Porta G; Oliveira CP
    Arq Gastroenterol; 2016; 53(2):118-22. PubMed ID: 27305420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated steatotic liver disease: Recent turning points for its diagnosis and management.
    Polyzos SA; Mantzoros CS
    Metabolism; 2024 Aug; 157():155936. PubMed ID: 38763229
    [No Abstract]   [Full Text] [Related]  

  • 6. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).
    Vos MB; Abrams SH; Barlow SE; Caprio S; Daniels SR; Kohli R; Mouzaki M; Sathya P; Schwimmer JB; Sundaram SS; Xanthakos SA
    J Pediatr Gastroenterol Nutr; 2017 Feb; 64(2):319-334. PubMed ID: 28107283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.
    Gao X; Fan JG;
    J Diabetes; 2013 Dec; 5(4):406-15. PubMed ID: 23560695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Alcoholic Fatty Liver Disease in HIV Infection.
    Macías J; Pineda JA; Real LM
    AIDS Rev; 2017; 19(1):35-46. PubMed ID: 28182612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Rauh C; Dufour JF
    Ther Umsch; 2017 Jul; 74(3):87-92. PubMed ID: 28777051
    [No Abstract]   [Full Text] [Related]  

  • 11. [Introduction to the APASL clinical guidelines on the management of metabolic-associated fatty liver disease].
    Shi YW; Xiao QQ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2020 Nov; 28(11):915-917. PubMed ID: 33256275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.
    Eslam M; Ahmed A; Després JP; Jha V; Halford JCG; Wei Chieh JT; Harris DCH; Nangaku M; Colagiuri S; Targher G; Joshi S; Byrne CD; Khunti K; Nguyen MH; Gish RG; George J
    Lancet Gastroenterol Hepatol; 2021 Sep; 6(9):743-753. PubMed ID: 34265276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
    Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
    World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [An interpretation of European guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease].
    Xin FZ; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):403-5. PubMed ID: 27465941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Watanabe S; Hashimoto E; Ikejima K; Uto H; Ono M; Sumida Y; Seike M; Takei Y; Takehara T; Tokushige K; Nakajima A; Yoneda M; Saibara T; Shiota G; Sakaida I; Nakamuta M; Mizuta T; Tsubouchi H; Sugano K; Shimosegawa T; ;
    J Gastroenterol; 2015 Apr; 50(4):364-77. PubMed ID: 25708290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress But With Challenges.
    Allen AM; Pose E; Reddy KR; Russo MW; Kamath PS
    Gastroenterology; 2024 Feb; 166(2):229-234. PubMed ID: 37949246
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of non-alcoholic fatty liver disease: an interpretation of the European clinical guidelines for obesity, type 2 diabetes, and digestive disease].
    He FP
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):119-121. PubMed ID: 28297798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.
    Ilagan-Ying YC; Banini BA; Do A; Lam R; Lim JK
    Curr Gastroenterol Rep; 2023 Oct; 25(10):213-224. PubMed ID: 37768417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathobiology of Metabolic-Associated Fatty Liver Disease.
    Fouda S; Jeeyavudeen MS; Pappachan JM; Jayanthi V
    Endocrinol Metab Clin North Am; 2023 Sep; 52(3):405-416. PubMed ID: 37495333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review.
    Schattenberg JM; Anstee QM; Caussy C; Bugianesi E; Popovic B
    Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1253-1266. PubMed ID: 34493137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.